Ellipticines as DNA-Targeted Chemotherapeutics
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11310%2F14%3A10282749" target="_blank" >RIV/00216208:11310/14:10282749 - isvavai.cz</a>
Result on the web
<a href="http://www.eurekaselect.com/115391/article" target="_blank" >http://www.eurekaselect.com/115391/article</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2174/09298673113206660272" target="_blank" >10.2174/09298673113206660272</a>
Alternative languages
Result language
angličtina
Original language name
Ellipticines as DNA-Targeted Chemotherapeutics
Original language description
The anti-tumor therapeutic ellipticine and its derivatives act as potent anticancer agents via a combined mechanism involving cell cycle arrest and induction of apoptosis. Cell death induced by ellipticine has been shown to engage a p53-dependent pathway, cell cycle arrest, interaction with several kinases and induction of the mitochondrial pathway of apoptotic cell death. Cell cycle arrest was shown to result from DNA damage caused by a variety of tumor chemotherapeutic agents; this is also the case for ellipticines. The prevalent DNA-mediated mechanisms of anti-tumor, mutagenic and cytotoxic activities of ellipticine are (i) intercalation into DNA, (ii) inhibition of DNA topoisomerase II activity, and (iii) covalent binding to DNA in vitro and in vivo after enzymatic activation by cytochrome P450 and/or peroxidase enzymes The mechanism leading to apoptosis by ellipticine is thought to also be associated with DNA damage, by inhibition of topoisomerase II and the covalent modification
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
CE - Biochemistry
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/GAP301%2F10%2F0356" target="_blank" >GAP301/10/0356: Study of contribution of different DNA-damaging mechanisms to toxicity of cytostatics to human chemosensitive and chemoresistant neuroblastomas</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Current Medicinal Chemistry
ISSN
0929-8673
e-ISSN
—
Volume of the periodical
21
Issue of the periodical within the volume
5
Country of publishing house
AE - UNITED ARAB EMIRATES
Number of pages
17
Pages from-to
575-591
UT code for WoS article
000331448500003
EID of the result in the Scopus database
—